17 May 2025 : Clinical Research
Pre-Chemotherapy D-Dimer Levels as Predictors of Survival Outcomes in Advanced Gastric Cancer
Yali Du ABCDEFG 1, Xuebing Jiang AD 1, Kaifei Fu ACF 1, Chengwen Cui ACDEF 2*DOI: 10.12659/MSM.947727
Med Sci Monit 2025; 31:e947727
Table 1 Baseline characteristics.
| Low pretreatment D-dimer (<1.5 ug/ml, n=89) | High pretreatment D-dimer (≥1.5 ug/ml, n=45) | P | |
|---|---|---|---|
| Median age, y | 63 (range: 32–78) | 64 (range: 29–79) | 0.276 |
| Sex | |||
| Male | 70 (78.7%) | 29 (64.4%) | 0.077 |
| Female | 19 (21.3%) | 16 (35.6%) | |
| Histology | |||
| p/d or p-m/d | 46 (95.8%) | 22 (88.0%) | 0.331 |
| m/d or m-w/d | 2 (4.2%) | 3 (12.0%) | |
| Pathological diagnosis | |||
| Adenocarcinoma | 81 (91.0%) | 41 (91.1%) | 0.495 |
| Signet-ring cell carcinoma | 3 (3.4%) | 3 (6.7%) | |
| Others | 5 (5.6%) | 1 (2.2%) | |
| Tumor location | |||
| Upper one-third | 44 (49.4%) | 15 (33.3%) | 0.025 |
| Middle one-third | 28 (31.5%) | 12 (26.7%) | |
| Lower one-third | 17 (19.1%) | 16 (35.6%) | |
| Whole | 0 | 2 (4.4%) | |
| Site of metastasis | |||
| Liver only | 18 (20.2%) | 8 (17.8%) | 0.162 |
| LN only | 20 (22.5%) | 8 (17.8%) | |
| LN+liver | 28 (31.5%) | 15 (33.3%) | |
| Abdominal | 20 (22.5%) | 7 (15.6%) | |
| Bone | 3 (3.4%) | 7 (15.6%) | |
| Tumor size | |||
| <50 cm | 84 (94.4%) | 43 (95.6%) | 1.000 |
| ≥50 cm | 5 (5.6%) | 2 (4.4%) | |
| Elevated CEA (n=76)# | 48 (63.2%) | 28 (36.8%) | 0.345 |
| Elevated CA199 (n=58)## | 34 (58.6%) | 24 (41.4%) | 0.092 |
| Elevated CA724 (n=53)* | 32 (60.4%) | 21 (39.6%) | 0.185 |
| Median no. Of CTx cycles | 8 (2–32) | 8 (2–27) | 0.653 |
| Best response | |||
| PR | 29 (32.6%) | 15 (33.3%) | 0.515 |
| SD | 45 (50.6%) | 19 (42.2%) | |
| PD | 15 (16.9%) | 11 (24.4%) | |
| Her-2 (n=124) | |||
| Positive | 7 (14.3%) | 8 (10.7%) | 0.546 |
| Negative | 42 (85.7%) | 67 (89.3%) | |
| p/d – poorly differentiated; m/d – moderately differentiated; p-m/d – poorly-moderately differentiated; m-w/d – moderately-well differentiated; PD – progressive disease; PR – partial response; SD – stable disease; CTx – chemotherapy; CEA – carcinoembryonic antigen; CA199 – carbohydrate antigen 199; CA724 – carbohydrate antigen 724; LN – lymph node. # Cutoff value of CEA: 3.5 ng/ml; ## cutoff value of CA199: 30u/ml; * cutoff value of CA724: 8.2 u/ml. | |||